

Mara Del Mar Tormo Daz

List of Publications by Citations

Source: <https://exaly.com/author-pdf/2213607/maria-del-mar-tormo-diaz-publications-by-citations.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

63
papers

1,060
citations

14
h-index

32
g-index

69
ext. papers

1,295
ext. citations

4.2
avg, IF

3.18
L-index

#	Paper	IF	Citations
63	Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. <i>Blood</i> , 2008 , 111, 3395-402	2.2	258
62	Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1595-604	2.2	181
61	Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens. <i>Blood</i> , 2011 , 117, 1799-805	2.2	95
60	Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. <i>Haematologica</i> , 2010 , 95, 424-31	6.6	72
59	Profile of polymorphisms of drug-metabolising enzymes and the risk of therapy-related leukaemia. <i>British Journal of Haematology</i> , 2007 , 136, 590-6	4.5	63
58	Feasibility and results of subtype-oriented protocols in older adults and fit elderly patients with acute lymphoblastic leukemia: Results of three prospective parallel trials from the PETHEMA group. <i>Leukemia Research</i> , 2016 , 41, 12-20	2.7	34
57	Influence of DNA damage and repair upon the risk of treatment related leukemia. <i>Leukemia and Lymphoma</i> , 2008 , 49, 204-17	1.9	31
56	Bone marrow fibrosis in myelodysplastic syndromes: a prospective evaluation including mutational analysis. <i>Oncotarget</i> , 2016 , 7, 30492-503	3.3	30
55	Prognostic significance of complex karyotype and monosomal karyotype in adult patients with acute lymphoblastic leukemia treated with risk-adapted protocols. <i>Cancer</i> , 2014 , 120, 3958-64	6.4	21
54	Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study. <i>Leukemia</i> , 2020 , 34, 3149-3160	10.7	19
53	A scoring system to predict the risk of death during induction with anthracycline plus cytarabine-based chemotherapy in patients with de novo acute myeloid leukemia. <i>Cancer</i> , 2012 , 118, 410-7	6.4	19
52	Considering Bone Marrow Blasts From Nonerythroid Cellularity Improves the Prognostic Evaluation of Myelodysplastic Syndromes. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3284-92	2.2	18
51	Unique clinico-biological, genetic and prognostic features of adult early T-cell precursor acute lymphoblastic leukemia. <i>Haematologica</i> , 2020 , 105, e294-e297	6.6	15
50	Myelodysplastic syndromes: an update on molecular pathology. <i>Clinical and Translational Oncology</i> , 2010 , 12, 652-61	3.6	15
49	Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative Study. <i>Leukemia</i> , 2020 , 34, 2333-2341	10.7	13
48	Increased survival due to lower toxicity for high-risk T-cell acute lymphoblastic leukemia patients in two consecutive pediatric-inspired PETHEMA trials. <i>European Journal of Haematology</i> , 2019 , 102, 79-86	3.8	13
47	Oxidative imbalance in low/intermediate-1-risk myelodysplastic syndrome patients: The influence of iron overload. <i>Clinical Biochemistry</i> , 2017 , 50, 911-917	3.5	11

46	Complex measurements may be required to establish the prognostic impact of immunophenotypic markers in AML. <i>American Journal of Clinical Pathology</i> , 2015 , 144, 484-92	1.9	11
45	Primary prophylaxis of invasive fungal infections with posaconazole or itraconazole in patients with acute myeloid leukaemia or high-risk myelodysplastic syndromes undergoing intensive cytotoxic chemotherapy: A real-world comparison. <i>Mycoses</i> , 2018 , 61, 206-212	5.2	11
44	Impact of mutational studies on the diagnosis and the outcome of high-risk myelodysplastic syndromes and secondary acute myeloid leukemia patients treated with 5-azacytidine. <i>Oncotarget</i> , 2018 , 9, 19342-19355	3.3	10
43	Pulmonary cytomegalovirus (CMV) DNA shedding in allogeneic hematopoietic stem cell transplant recipients: Implications for the diagnosis of CMV pneumonia. <i>Journal of Infection</i> , 2019 , 78, 393-401	18.9	9
42	A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patients. <i>Leukemia Research</i> , 2019 , 76, 1-10	2.7	9
41	Patterns of care and clinical outcomes of patients with newly diagnosed acute myeloid leukemia presenting with hyperleukocytosis who do not receive intensive chemotherapy. <i>Leukemia and Lymphoma</i> , 2020 , 61, 1220-1225	1.9	8
40	Impact of clinical features, cytogenetics, genetic mutations, and methylation dynamics of CDKN2B and DLC-1 promoters on treatment response to azacitidine. <i>Annals of Hematology</i> , 2020 , 99, 527-537	3	7
39	An analysis of the impact of CD56 expression in de novo acute promyelocytic leukemia patients treated with upfront all-trans retinoic acid and anthracycline-based regimens. <i>Leukemia and Lymphoma</i> , 2019 , 60, 1030-1035	1.9	7
38	Evolving treatment patterns and outcomes in older patients (≥80 years) with AML: changing everything to change nothing?. <i>Leukemia</i> , 2021 , 35, 1571-1585	10.7	7
37	Frequency and prognostic significance of t(v;11q23)/KMT2A rearrangements in adult patients with acute lymphoblastic leukemia treated with risk-adapted protocols. <i>Leukemia and Lymphoma</i> , 2017 , 58, 145-152	1.9	6
36	Acute myeloid leukemia with inv(3)(q21.3q26.2)/t(3;3)(q21.3;q26.2): Study of 61 patients treated with intensive protocols. <i>European Journal of Haematology</i> , 2020 , 105, 138-147	3.8	5
35	An XRCC1 polymorphism is associated with the outcome of patients with lymphoma undergoing autologous stem cell transplant. <i>Leukemia and Lymphoma</i> , 2011 , 52, 1249-54	1.9	5
34	A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia. <i>Cancer</i> , 2021 , 127, 2003-2014	6.4	5
33	Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1. <i>Blood Advances</i> , 2021 ,	7.8	5
32	The poor prognosis of low hypodiploidy in adults with B-cell precursor acute lymphoblastic leukaemia is restricted to older adults and elderly patients. <i>British Journal of Haematology</i> , 2019 , 186, 263-268	4.5	4
31	Early adjustment of empirical antibiotic therapy of bloodstream infections on the basis of direct identification of bacteria by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and Gram staining results. <i>Journal of Infection and Chemotherapy</i> , 2020 , 26, 963-969	2.2	4
30	Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA and chemotherapy. <i>Leukemia and Lymphoma</i> , 2019 , 60, 1146-1155	1.9	4
29	SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders.. <i>Journal of Hematology and Oncology</i> , 2022 , 15, 54	22.4	4

28	Synergistic Antioncogenic Activity of Azacitidine and Curcumin in Myeloid Leukemia Cell Lines and Patient Samples. <i>Anticancer Research</i> , 2019 , 39, 4757-4766	2.3	3
27	Differences in Chemosensitivity to Anthracyclines in First Line Acute Myeloid Leukemia. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2019 , 11, e2019016	3.2	3
26	Prognostic Value of Monosomal Karyotype in Patients with Primary Acute Myeloid Leukemia On Behalf of Spanish CETLAM Group.. <i>Blood</i> , 2009 , 114, 1003-1003	2.2	3
25	Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study. <i>Blood Advances</i> , 2021 ,	7.8	3
24	Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients. <i>Leukemia and Lymphoma</i> , 2021 , 1-13	1.9	3
23	Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trial. <i>Blood Advances</i> , 2021 , 5, 760-770	7.8	3
22	Adverse prognostic impact of complex karyotype (B cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL). <i>Leukemia Research</i> , 2021 , 109, 106612	2.7	3
21	Treatment of Frail Older Adults and Elderly Patients With Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia: Results of a Prospective Trial With Minimal Chemotherapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020 , 20, e513-e522	2	2
20	Bone marrow VEGFC expression is associated with multilineage dysplasia and several prognostic markers in adult acute myeloid leukemia, but not with survival. <i>Leukemia and Lymphoma</i> , 2018 , 59, 2383-2393	1.9	1
19	Therapy-related acute myeloid leukemia developing 14 years after allogeneic hematopoietic stem cell transplantation, from a persistent R882H-DNMT3A mutated clone of patient origin. <i>Experimental and Molecular Pathology</i> , 2018 , 105, 139-143	4.4	1
18	Genomic Data Improves Prognostic Stratification in Adult T-Cell Acute Lymphoblastic Leukemia Patients Enrolled in Measurable Residual Disease-Oriented Trials. <i>Blood</i> , 2021 , 138, 3486-3486	2.2	1
17	Clinical significance of <i>Pneumocystis jirovecii</i> DNA detection by real-time PCR in hematological patient respiratory specimens. <i>Journal of Infection</i> , 2020 , 80, 578-606	18.9	1
16	The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical Trial. <i>Cancers</i> , 2021 , 13,	6.6	1
15	Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and genetic mutations. <i>British Journal of Haematology</i> , 2021 , 194, 708-717	4.5	1
14	A Predictive Model for Early Death after Frontline Hypomethylating Agents in Elderly Unfit Acute Myeloid Leukemia Patients: Results from the Pethema Group. <i>Blood</i> , 2019 , 134, 648-648	2.2	0
13	Outcomes and prognostic factors of adults with refractory or relapsed T-cell acute lymphoblastic leukemia included in measurable residual disease-oriented trials. <i>Hematological Oncology</i> , 2021 , 39, 529-538	1.3	0
12	Practical tips for managing FLT3 mutated acute myeloid leukemia with midostaurin.. <i>Expert Review of Hematology</i> , 2022 , 1-12	2.8	0
11	Acute leukemia arising from myeloproliferative or myelodysplastic/myeloproliferative neoplasms: A series of 372 patients from the PETHEMA AML registry.. <i>Leukemia Research</i> , 2022 , 115, 106821	2.7	0

10	Cytomegalovirus DNAemia in patients with acute myeloid leukemia undergoing cytotoxic chemotherapy. <i>Leukemia and Lymphoma</i> , 2019 , 60, 3081-3083	1.9
9	Acute Myeloid Leukemia with Isocitrate Dehydrogenases (IDH) 1 and 2 Mutations. a Real-World Study from the European IDH Research Group. <i>Blood</i> , 2020 , 136, 30-31	2.2
8	Triple Negative Myelofibrosis and Myelodysplastic Syndrome with Fibrosis: Clinico-Biological Characterization and Correlation with Gene Mutations. <i>Blood</i> , 2018 , 132, 4299-4299	2.2
7	Clinical Significance of Myelofibrotic (MF) Changes in Myelodysplastic Syndromes (MDS): A Prospective Evaluation Including Mutational Analysis By Next-Generation Sequencing (NGS). <i>Blood</i> , 2014 , 124, 4652-4652	2.2
6	Allogeneic Hematopoietic Stem-Cell Transplantation (HSCT) in First Complete Remission Is Superior Compared to Chemotherapy/Autologous HSCT in Patients with Intermediate-Risk Cytogenetics Acute Myeloid Leukemia Lacking Mutations in NPM1, FLT3-ITD, and CEBPA: A Joint Study of AMLSG, Cetlam and Acute Leukemia Working Party of EBMT. <i>Blood</i> , 2014 , 124, 324-324	2.2
5	The LincRNA HOTAIRM1, Located in the HOXA genomic Region, impacts Prognosis in Acute Myeloid Leukemia and Is Associated with a Distinctive microRNA Signature. <i>Blood</i> , 2014 , 124, 1003-1003 ^{2,2}	2.2
4	Azacitidine in older patients with acute myeloid leukemia (AML). Results from the ALMA study according to the MRC risk index score.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 7061-7061	2.2
3	An ex vivo native environment precision medicine AML test and the correlation with responses to 1st line treatment.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e18510-e18510	2.2
2	Prognostic Impact of the Levels of Expression of Cell Surface Proteins Commonly Expressed by Blasts and Hematopoietic Precursor Cells in De Novo AML Patients: A Report From the Spanish Cetlam Study Group. <i>Blood</i> , 2012 , 120, 1452-1452	2.2
1	Evolving patterns of care and outcomes in relapsed/refractory FLT3 mutated acute myeloid leukemia adult patients. <i>Leukemia and Lymphoma</i> , 2021 , 62, 2727-2736	1.9